We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+4.14%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$3.14B
AUM Growth
+$264M
Cap. Flow
+$471M
Cap. Flow %
15.02%
Top 10 Hldgs %
65.37%
Holding
91
New
20
Increased
10
Reduced
3
Closed
15

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$159M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$94.1M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$83.8M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$61.6M
5
TSVT
2seventy bio
TSVT
+$59.8M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$82.1M
2
STTK icon
Shattuck Labs
STTK
+$75.6M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$25.2M
4
NRIX icon
Nurix Therapeutics
NRIX
+$24.8M
5
BLUE
bluebird bio
BLUE
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.9%
2 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EWTX icon
26
Edgewise Therapeutics
EWTX
$4.48B
$19.5M 0.62%
1,279,175
– –
OVID icon
27
Ovid Therapeutics
OVID
$439M
$19.5M 0.62%
6,082,200
– –
AKUS
28
DELISTED
Akouos Inc
AKUS
$16.8M 0.54%
1,975,984
– –
CRNX icon
29
Crinetics Pharmaceuticals
CRNX
$8.87B
$16.8M 0.53%
+590,169
New +$14.5M
ALNY icon
30
Alnylam Pharmaceuticals
ALNY
$37.2B
$16.6M 0.53%
+98,146
New +$18.2M
SLDB icon
31
Solid Biosciences
SLDB
$777M
$16.1M 0.51%
613,513
– –
HALO icon
32
Halozyme
HALO
$9.66B
$15.8M 0.5%
+392,000
New +$14.6M
LEGN icon
33
Legend Biotech
LEGN
$3.73B
$14.3M 0.46%
+307,594
New +$15.6M
TNGX icon
34
Tango Therapeutics
TNGX
$4.35B
$14.2M 0.45%
1,300,000
– –
ERAS icon
35
Erasca
ERAS
$6.55B
$10.9M 0.35%
700,000
– –
ARVN icon
36
Arvinas
ARVN
$530M
$10.7M 0.34%
+130,300
New +$10.6M
CNTA
37
DELISTED
Centessa Pharmaceuticals
CNTA
$9.93M 0.32%
882,176
+127,631
+17% +$1.72M
IMVT icon
38
Immunovant
IMVT
$8.23B
$9.72M 0.31%
1,140,819
– –
VYGR icon
39
Voyager Therapeutics
VYGR
$187M
$9.64M 0.31%
3,557,507
+3,111,515
+698% +$10.6M
NRIX icon
40
Nurix Therapeutics
NRIX
$2.43B
$8.96M 0.29%
309,540
-817,100
-73% -$24.8M
LENZ
41
LENZ Therapeutics
LENZ
$179M
$8.56M 0.27%
+98,414
New +$8.15M
NUVB.WS
42
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$8.19M 0.26%
963,333
– –
SPRY icon
43
ARS Pharmaceuticals
SPRY
$572M
$7.06M 0.23%
1,060,010
-124,700
-11% -$1.01M
CCCC icon
44
C4 Therapeutics
CCCC
$397M
$6.44M 0.21%
200,000
– –
FLAC
45
DELISTED
Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares
FLAC
$5.73M 0.18%
587,615
– –
AMTI
46
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$5.59M 0.18%
+400,000
New +$7.89M
KRON
47
DELISTED
Kronos Bio
KRON
$5.26M 0.17%
387,357
– –
JYAC
48
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.88M 0.16%
500,000
– –
NGNE icon
49
Neurogene
NGNE
$691M
$4.15M 0.13%
43,031
– –
OBIO icon
50
Orchestra BioMed
OBIO
$229M
$4.03M 0.13%
400,000
– –
1
2
3 4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q4 2021 Portfolio in Review

As of Q4 2021, EcoR1 Capital held 91 positions worth $3.14B, up 9.2% from $2.87B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

EcoR1 Capital deployed $471M of net new capital in Q4 2021, opening 20 new positions and adding to 10 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 4,033,882 shares worth $191M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Nurix Therapeutics, an estimated $24.8M trimmed.

  • EcoR1 Capital's largest Q4 2021 buy was Apellis Pharmaceuticals: 4,033,882 shares worth $191M.
  • EcoR1 Capital added most to Protagonist Therapeutics in Q4 2021, an estimated $37.8M increase.
  • EcoR1 Capital's biggest Q4 2021 reduction was Nurix Therapeutics, cutting an estimated $24.8M.
  • EcoR1 Capital fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2021, selling an estimated $82.1M.
  • EcoR1 Capital's ten largest holdings make up 65% of its $3.14B portfolio in Q4 2021.
  • EcoR1 Capital opened 20 new positions and closed 15 in Q4 2021.
  • EcoR1 Capital's portfolio value rose 9.2% quarter-over-quarter to $3.14B.

Based on EcoR1 Capital's 13F filing for Q4 2021, filed 14 Feb 2022.